초록

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.

대표청구항 ▼

1. An isolated antibody having the ability of binding to a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 3-10 and 35-79 and mediating inhibition of proliferation of cells expressing a protein comprising the amino acid sequence of SEQ ID NO: 2 and/or ar

1. An isolated antibody having the ability of binding to a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 3-10 and 35-79 and mediating inhibition of proliferation of cells expressing a protein comprising the amino acid sequence of SEQ ID NO: 2 and/or are characterized by association of a protein comprising the amino acid sequence of SEQ ID NO: 2 with the cell surface. 2. The isolated antibody of claim 1, wherein said inhibition of proliferation of said cells is induced by binding of said antibody to a protein comprising the amino acid sequence of SEQ ID NO: 2 expressed by said cells and/or associated with the surface of said cells. 3. The isolated antibody of claim 2, wherein said antibody binds to the extracellular domain of a protein comprising the amino acid sequence of SEQ ID NO: 2 expressed by said cells and/or associated with the surface of said cells. 4. The isolated antibody of claim 1, wherein said cells are cancer cells. 5. The isolated antibody of claim 4, wherein said cancer cells are selected from the group consisting of tumorigenic breast, lung, gastric, ovarian, liver, colon, pancreatic, esophageal, head-neck, renal, prostate and hepatocellular cancer cells. 6. The isolated antibody of claim 1 which is a monoclonal, chimeric, human or humanized antibody, or an antigen-binding fragment of an antibody. 7. The isolated antibody of claim 1 selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, an IgM, an IgA1, an IgA2, a secretory IgA, an IgD, and an IgE antibody. 8. The isolated antibody of claim 7 selected from the group consisting of an IgG2a and IgG2b antibody. 9. The isolated antibody of claim 1, wherein the antibody binds specifically to a protein comprising the amino acid sequence of SEQ ID NO: 2. 10. The isolated antibody of claim 1 which binds to native epitopes of a protein comprising the amino acid sequence of SEQ ID NO: 2 present on the surface of living cells. 11. The isolated antibody of claim 1, wherein said protein comprising the amino acid sequence of SEQ ID NO: 2 is expressed on the surface of said cells. 12. A hybridoma or recombinant cell producing the antibody of claim 1. 13. An antibody produced by the hybridoma or recombinant cell of claim 12. 14. A conjugate comprising the antibody of claim 1 coupled to a therapeutic agent. 15. The conjugate of claim 14, wherein the therapeutic agent is a toxin, a radioisotope, a drug or a cytotoxic agent. 16. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier. 17. A pharmaceutical composition comprising the antibody of claim 13 and a pharmaceutically acceptable carrier. 18. A pharmaceutical composition comprising the conjugate of claim 14 and a pharmaceutically acceptable carrier.